| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 129.56B | 122.07B | 103.35B | 87.43B | 77.82B | 62.14B | 
| Gross Profit | 84.65B | 87.18B | 70.14B | 33.88B | 53.12B | 43.89B | 
| EBITDA | 34.10B | 30.18B | 28.09B | 20.27B | 21.47B | 18.17B | 
| Net Income | 18.93B | 19.91B | 19.13B | 12.82B | 14.33B | 12.65B | 
| Balance Sheet | ||||||
| Total Assets | 0.00 | 277.60B | 119.63B | 97.15B | 91.48B | 63.73B | 
| Cash, Cash Equivalents and Short-Term Investments | 25.25B | 22.45B | 34.56B | 15.29B | 12.79B | 20.04B | 
| Total Debt | 0.00 | 85.11B | 2.07B | 1.70B | 8.73B | 2.41B | 
| Total Liabilities | -145.68B | 131.91B | 23.87B | 20.67B | 28.31B | 15.10B | 
| Stockholders Equity | 145.68B | 143.32B | 93.63B | 74.35B | 61.55B | 47.22B | 
| Cash Flow | ||||||
| Free Cash Flow | 0.00 | 19.53B | 17.70B | 9.53B | -14.26B | 8.25B | 
| Operating Cash Flow | 0.00 | 24.13B | 21.52B | 17.85B | 9.20B | 11.37B | 
| Investing Cash Flow | 0.00 | -126.92B | -20.82B | -10.54B | -13.69B | -12.22B | 
| Financing Cash Flow | 0.00 | 102.33B | 52.66M | -7.40B | 6.05B | -78.11M | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ₹630.26B | 18.58 | ― | 0.36% | 7.76% | -2.84% | |
| ― | ₹1.27T | 23.63 | ― | 0.82% | 6.40% | 25.27% | |
| ― | ₹993.45B | 21.73 | ― | 1.10% | 14.52% | 9.46% | |
| ― | ₹877.48B | 23.70 | ― | 0.62% | 12.40% | 63.16% | |
| ― | ₹1.21T | 60.49 | ― | 0.89% | 7.63% | 15.39% | |
| ― | ₹1.02T | 53.21 | ― | 0.04% | 21.66% | -4.92% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | 
Mankind Pharma Limited has announced that it has not received any requests for dematerialisation or rematerialisation of shares for the quarter ending September 30, 2025. This update, certified by KFin Technologies Limited, aligns with the company’s adherence to SEBI (Depositories and Participants) Regulations, 2018, ensuring transparency and compliance in its share management practices.
Mankind Pharma Ltd. announced that the penalty of ₹2,90,70,363 imposed by the CGST Commissionerate, Meerut, for the financial years 2017-18 to 2021-22, has been withdrawn following an appeal. This development is likely to have a positive impact on the company’s financial standing and may enhance its reputation among stakeholders by demonstrating effective legal and regulatory compliance.
Mankind Pharma Ltd. has announced its participation in the upcoming Jefferies 4th India Forum, scheduled for September 17, 2025, in Gurugram. The event will include one-on-one and group meetings, allowing the company’s management to engage with investors. This participation underscores Mankind Pharma’s proactive approach to investor relations and its commitment to transparency, although no unpublished price-sensitive information will be disclosed during the conference.
Mankind Pharma Ltd. has received an ESG rating of ‘Crisil ESG 57’ from Crisil ESG Ratings & Analytics Limited, indicating an ‘adequate’ level of environmental, social, and governance practices. This rating reflects the company’s efforts in maintaining transparency and responsibility in its operations, potentially impacting its reputation and attractiveness to investors focused on sustainable practices.
Mankind Pharma Ltd. released the transcript of its Q1 FY26 investor conference call, highlighting the company’s financial performance and strategic direction. The call, led by key executives, provided insights into the company’s operations and market positioning, potentially impacting stakeholders’ perspectives on its future growth and industry influence.
Mankind Pharma Ltd. has submitted an application to reclassify Ayushi and Poonam Estates LLP from the ‘Promoter & Promoter Group’ category to the ‘Public’ category. This move is part of the company’s strategic efforts to align with regulatory requirements and potentially enhance its market positioning by broadening its public shareholder base.